Project:Intensive Habilitation (PIH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00202761|
Recruitment Status : Active, not recruiting
First Posted : September 20, 2005
Last Update Posted : December 8, 2016
The purpose of this study is to document that taking part in this program is beneficial for the child, its parents and local professionals.
The study hypothesis are:
Intensive training will speed up the childs motor, cognitive and social development.
Intensive habilitation will increase the childs family's empowerment Children having participated in this intensive habilitation will speed up their process of development further than children in the control group The cooperation between first and second line health service is strengthened by participation in the intensive habilitation program The professionals in the first line(community)in Norway that participates in this program increases their empowerment and motivation
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Palsy||Behavioral: PIH||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities|
|Study Start Date :||March 2004|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
- PEDI [ Time Frame: dec 2006 ]
- PSI [ Time Frame: Dec 2006 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00202761
|Sorlandet Hospital HF|
|Kristiansand, Norway, 4604|
|Principal Investigator:||Jon Skranes, MD, PhD||Sorlandet Hospital HF|